Dergiler / art / 2014 / Cilt: 29 - Sayı: 1

The correlation between the molecular heterogeneity of prolactin and autoantibody and complement levels in patients with systemic lupus erythematosus

Dergi
art
Sayfa
35–41
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusion: The activity disease of SLE patients was correlated with the level of small PRL but not with total PRL.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objectives: This study aims to investigate the relationship between the molecular heterogeneity of prolactin (PRL) and anti-double- stranded deoxyribonucleic acid (anti-dsDNA), anti-C1q, and complement 3 (C3) levels in patients with systemic lupus erythematosus (SLE).
📊
Temel Bulgular & Veri:Patients and methods: This study included 30 premenopausal females with SLE from the Rheumatology Clinic of Doctor Saiful Anwar General Hospital in Malang, Indonesia and 30 healthy females as the control group.
💡
Sonuç & Katkı:Conclusion: The activity disease of SLE patients was correlated with the level of small PRL but not with total PRL.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objectives: This study aims to investigate the relationship between the molecular heterogeneity of prolactin (PRL) and anti-double- stranded deoxyribonucleic acid (anti-dsDNA), anti-C1q, and complement 3 (C3) levels in patients with systemic lupus erythematosus (SLE). Patients and methods: This study included 30 premenopausal females with SLE from the Rheumatology Clinic of Doctor Saiful Anwar General Hospital in Malang, Indonesia and 30 healthy females as the control group. Prolactin heterogeneity (small and large) was determined using the ultra filtration method and electrochemiluminescence immunoassay, while the total PRL, anti-dsDNA, anti-C1q, and C3 serum levels were measured by enzyme-linked immunosorbent assay. Results: The mean total PRL and small PRL serum levels for the SLE patients were 13.83±8.78 ng/mL and 4.45±1.88 ng/mL, respectively, whereas they were 9.14±3.85 ng/mL and 2.49±0.29 ng/mL, respectively for the healthy controls, indicating a significant difference between the groups (p=0.01 and p=0.00, respectively). Significant correlations were found between the small PRL serum levels and the anti-dsDNA (r=0.978; p=0.00) and C3 (r= -0.970; p=0.00) levels. Conclusion: The activity disease of SLE patients was correlated with the level of small PRL but not with total PRL.

🔖

Bu Makaleye Atıf Yap

HANDONO, K., STRISNANI, C. S., ANGGRAENY, O., RACHMAWATI, E., ENDHARTI, A. T., ARTHAMIN, M. Z. (2014). The correlation between the molecular heterogeneity of prolactin and autoantibody and complement levels in patients with systemic lupus erythematosus. art, Cilt: 29 - Sayı: 1, 35–41. https://ajindex.com/articles/351752

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Leaños-Miranda A, Cárdenas-Mondragón G. Serum free prolactin concentrations in patients with systemic lupus erythematosus are associated with lupus activity. Rheumatology (Oxford) 2006;45:97–101
  2. Tiskievicz F, Mallmann ES, Brenol JC, Xavier RM, Spritzer PM. Prolactin, estradiol and anticardiolipin antibodies in premenopausal women with systemic lupus erythematosus: a pilot study. Rev Bras Reumatol 2011;51:460–4
  3. Zen M, Ghirardello A, Iaccarino L, Tonon M, Campana C, Arienti S, Rampudda M, et al. Hormones, immune response, and pregnancy in healthy women and SLE patients. Swiss Med Wkly 2010;140:187–201
  4. Peeva E, Zouali M. Spotlight on the role of hormonal factors in the emergence of autoreactive B-lymphocytes. Immunol Lett 2005;101:123–43
  5. Orbach H, Shoenfeld Y. Hyperprolactinemia and autoimmune diseases. Autoimmun Rev 2007;6:537– 42
  6. De-Bellis, Savoia A, Battaglia M, Coronella C, Tirelli G, Ruocco G, et al. Report: Prolactin in Autoimmune Disease. European Endocrine Disease 2006;51–52
  7. Vera-Lastra O, Jara LJ, Espinoza LR. Prolactin and autoimmunity. Autoimmun Rev 2002;1:360–4
  8. García M, Colombani-Vidal ME, Zylbersztein CC, Testi A, Marcos J, Arturi A, et al. Analysis of molecular heterogeneity of prolactin in human systemic lupus erythematosus. Lupus 2004;13:575–83
  9. Chuang E, Molitch ME. Prolactin and autoimmune diseases in humans. Acta Biomed 2007;78 Suppl 1:255–61
  10. Sangle, SR Lin, Sanchez LY, Rachel E, D'Cruz D, David P. Anti C1q antibodies in patients with systemic lupus erythematosus and cutaneous vasculitis: a controlled study. Arthritis Rheum 2010;62 Suppl 10:444. [Abstract] 11. Cruz J, Aviña-Zubieta A, Martínez de la Escalera G, Clapp C, Lavalle C. Molecular heterogeneity of prolactin in the plasma of patients with systemic lupus erythematosus. Arthritis Rheum 2001;44:1331–5
  11. Beda-Maluga K, Pisarek H, Komorowski J, Pawlikowski M, Swietosławski J, Winczyk K. The detection of macroprolactin by precipitation and ultrafiltration methods. Endokrynol Pol 2011;62:529–36
  12. Endharti AT, Rifa’I M, Shi Z, Fukuoka Y, Nakahara Y, Kawamoto Y, et al. Cutting edge: CD8+CD122+ regulatory T cells produce IL-10 to suppress IFN-gamma production and proliferation of CD8+ T cells. J Immunol 2005;175:7093–7
  13. Jara LJ, Vera-Lastra O, Miranda JM, Alcala M, Alvarez-Nemegyei J. Prolactin in human systemic lupus erythematosus. Lupus 2001;10:748–56
  14. Ostendorf B, Fischer R, Santen R, Schmitz-Linneweber B, Specker C, Schneider M. Hyper